Plus, news about BrightGene and Apogee Therapeutics: 📊 More data on Novo Nordisk-United triple-G: The Danish drugmaker said its China-derived triple-G agonist led to mean

Spanish plasma medicine specialist Grifols is planning to sell a minority stake in its US business, via an IPO, to help pay down its debt.

Fourteen years ago, a group of Harvard Business School students launched a startup called Vaxess Technologies with a goal to disrupt the vaccine industry by

Novo Nordisk has reported the first clinical data with its triple G agonist for diabetes, in China, as it starts an international trials programme.

Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same